A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
Clinical trial NCT03778957 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03778957
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-30
- Primary completion
- 2023-09-11
- Enrollment
- 724
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.